Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05494580CT.gov Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Carcinosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pamiparib (this asset) | Sun Yat-sen University | P1/2 | CCC · 48 |
| Adriamycin | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | Mayo Clinic | P2 | B |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | B |
| Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | Mayo Clinic | P2 | CCC |
| Tetanus Toxoid | Mayo Clinic | P2 | CCC |
| Diphtheria Toxoid | Mayo Clinic | P2 | CCC |
| Adsorbed Purified Pertussis Vaccine | Mayo Clinic | P2 | CCC |
| Diphtheria Toxoid Adsorbed | Mayo Clinic | P2 | CCC |
+12 more in the Fallopian Tube Carcinosarcoma cohort
Other indications for Pamiparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | B · 58 |
| Ovarian Cancer | — | P3 | B · 58 |
| Grade II Glioma | — | P1/2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pamiparib in Fallopian Tube Carcinosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pamiparib-fallopian-tube-carcinosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →